Who Paid My Doc
Amanda Boardman
Nurse Practitioner, Acute Care Omaha, NE Nurse Practitioner
NPI 1902141286 CMS profile 10504600
7500 Mercy Rd, Omaha, NE 68101
General payments
$575
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Amanda Boardman of Omaha, NE is reported in the CMS Open Payments database as having received $575 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 64th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $123 | 1 | |
| 2022 | General | $141 | 3 | |
| 2021 | General | $310 | 11 |
Beside peers
- Amanda Boardman
- Nurse Practitioner, Acute Care median
- Middle half of Nurse Practitioner, Acute Care
- National median
In program year 2025, general payments to Amanda Boardman were reported at $123. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.
Show as a table
| Year | Amanda Boardman | Nurse Practitioner, Acute Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $310 | $123 | $38–$327 | $132 |
| 2022 | $141 | $130 | $44–$369 | $149 |
| 2023 | $0 | $144 | $49–$410 | $160 |
| 2024 | $0 | $146 | $48–$433 | $164 |
| 2025 | $123 | $152 | $48–$458 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
280
Drug cost
$15,881
Branded share of claims
20.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 15 | $8,732 | |
| Brilinta Ticagrelor | Brand | 12 | $5,490 | |
| Atorvastatin Calcium | Generic | 31 | $279 | |
| Amiodarone Hcl | Generic | 26 | $276 | |
| Metoprolol Succinate | Generic | 29 | $272 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 30 | $267 | |
| Gabapentin | Generic | 17 | $156 | |
| Metoprolol Tartrate | Generic | 44 | $136 | |
| Potassium Chloride | Generic | 26 | $117 | |
| Methocarbamol | Generic | 14 | $108 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nurse Practitioner, Acute Care in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Acute Care
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.